/TXG
TXG Stock - 10x Genomics, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$16.05+0.31%
+$0.05 (+0.31%) • Dec 19
74
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.90
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.34
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+30.8%upside
Target: $20.99
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TXG
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.89 – $16.21
TARGET (TP)$21.00
STOP LOSS$14.77
RISK/REWARD1:3.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.15
52W High$20.34
52W Low$6.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $610.78M | $618.73M | $516.41M | $490.49M | $298.85M |
| Gross Profit | $414.48M | $409.31M | $396.02M | $416.40M | $240.38M |
| Gross Margin | 67.9% | 66.2% | 76.7% | 84.9% | 80.4% |
| Operating Income | $-194,559,000 | $-265,329,000 | $-167,944,000 | $-52,913,000 | $-85,324,000 |
| Net Income | $-182,627,000 | $-255,099,000 | $-166,000,000 | $-58,223,000 | $-542,731,000 |
| Net Margin | -29.9% | -41.2% | -32.1% | -11.9% | -181.6% |
| EPS | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 |
Company Overview
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
33%
Hold / Neutral
10
56%
Sell / Underperform
2
11%
Analyst Consensus🔴 Bearish
6 Bullish12 Neutral/Bearish
Price Targets
$40
Average Target
↑ 148.0% Upside
Now
$12
Low
$40
Average
$65
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 11th 2025 | Citigroup | Downgrade | Neutral | - |
| December 2nd 2025 | Morgan Stanley | Downgrade | Equal Weight | $20 |
| September 11th 2025 | Piper Sandler | Initiation | Neutral | $15 |
| February 13th 2025 | Leerink Partners | Downgrade | Market Perform | $12← $25 |
| September 3rd 2024 | Leerink Partners | Initiation | Outperform | $35 |
| July 22nd 2024 | Jefferies | Upgrade | Buy | $24 |
| July 18th 2024 | JP Morgan | Downgrade | Neutral | $20← $40 |
| July 10th 2024 | Deutsche Bank | Downgrade | Hold | $25← $55 |
| June 27th 2024 | Wolfe Research | Downgrade | Peer Perform | - |
| June 25th 2024 | Guggenheim | Downgrade | Neutral | - |
| June 3rd 2024 | Jefferies | Resumed | Hold | $24 |
| May 1st 2024 | TD Cowen | Downgrade | Hold | $32← $57 |
| December 14th 2023 | Guggenheim | Initiation | Buy | $60 |
| December 13th 2023 | Wolfe Research | Initiation | Outperform | $55 |
| December 12th 2023 | BofA Securities | Upgrade | Neutral | $54← $36 |
Earnings History & Surprises
TXGBeat Rate
44%
Last 18 quarters
Avg Surprise
-9.1%
EPS vs Estimate
Beats / Misses
8/10
Last 12 quarters
Latest EPS
$-0.22
Q4 2025
EPS Surprise History
Q1 24
-13.9%
$-0.41vs$-0.36
Q2 24
-8.7%
$-0.50vs$-0.46
Q3 24
+31.9%
$-0.32vs$-0.47
Q4 24
+11.8%
$-0.30vs$-0.34
Q1 25
-37.9%
$-0.40vs$-0.29
Q2 25
+20.0%
$-0.36vs$-0.45
Q3 25
+180.0%
$0.28vs$-0.35
Q4 25
-214.3%
$-0.22vs$-0.07
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Feb 11, 2026 | $-0.20 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.07 | $-0.22 | -214.3% | ✗ MISS |
Q3 2025 | Aug 7, 2025 | $-0.35 | $0.28 | +180.0% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.45 | $-0.36 | +20.0% | ✓ BEAT |
Q1 2025 | Feb 12, 2025 | $-0.29 | $-0.40 | -37.9% | ✗ MISS |
Q4 2024 | Oct 29, 2024 | $-0.34 | $-0.30 | +11.8% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.47 | $-0.32 | +31.9% | ✓ BEAT |
Q2 2024 | Apr 30, 2024 | $-0.46 | $-0.50 | -8.7% | ✗ MISS |
Q1 2024 | Feb 15, 2024 | $-0.36 | $-0.41 | -13.9% | ✗ MISS |
Q4 2023 | Nov 2, 2023 | $-0.45 | $-0.51 | -13.3% | ✗ MISS |
Q3 2023 | Aug 3, 2023 | $-0.39 | $-0.53 | -35.9% | ✗ MISS |
Q2 2023 | May 3, 2023 | $-0.38 | $-0.44 | -15.8% | ✗ MISS |
Q1 2023 | Feb 15, 2023 | $-0.29 | $-0.15 | +48.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.45 | $-0.37 | +17.8% | ✓ BEAT |
Q3 2022 | Aug 8, 2022 | $-0.40 | $-0.57 | -42.5% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-0.37 | $-0.38 | -2.7% | ✗ MISS |
Q1 2022 | Feb 16, 2022 | $-0.06 | $-0.16 | -166.7% | ✗ MISS |
Q4 2021 | Nov 3, 2021 | $-0.18 | $-0.15 | +16.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.26 | $-0.10 | +61.5% | ✓ BEAT |
Latest News
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $22
📈 PositiveBenzinga•Dec 15, 2025, 08:54 PM•Also:
Citigroup Downgrades 10x Genomics to Neutral, Announces $18 Price Target
➖ NeutralBenzinga•Dec 11, 2025, 08:55 PM•Also:
Morgan Stanley Downgrades 10x Genomics to Equal-Weight, Raises Price Target to $20
➖ NeutralBenzinga•Dec 2, 2025, 02:23 PM
Piper Sandler Maintains Neutral on 10x Genomics, Raises Price Target to $19
➖ NeutralBenzinga•Nov 11, 2025, 05:14 PM
Canaccord Genuity Maintains Buy on 10x Genomics, Raises Price Target to $19
📈 PositiveBenzinga•Nov 7, 2025, 10:11 PM•Also:
JP Morgan Maintains Neutral on 10x Genomics, Raises Price Target to $15
➖ NeutralBenzinga•Nov 7, 2025, 07:37 PM
UBS Maintains Neutral on 10x Genomics, Raises Price Target to $14
➖ NeutralBenzinga•Nov 7, 2025, 05:58 PM•Also:
Barclays Maintains Overweight on 10x Genomics, Raises Price Target to $17
📈 PositiveBenzinga•Nov 7, 2025, 03:00 PM•Also:
10x Genomics shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates.
📈 PositiveBenzinga•Nov 7, 2025, 02:11 PM
10x Genomics shares are trading higher after the company reported better-than-expected Q3 financial results and issued Q4 sales guidance above estimates.
📈 PositiveBenzinga•Nov 6, 2025, 09:54 PM
10x Genomics Sees Q4 Sales $154.000M-$158.000M vs $151.048M Est
📈 PositiveBenzinga•Nov 6, 2025, 09:29 PM
10x Genomics Q3 EPS $(0.22) Beats $(0.29) Estimate, Sales $149.002M Beat $142.490M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 09:28 PM
10x Genomics Rolls Out Flex Assay To Offer Cost-Effective Single Cell Analysis
📈 PositiveBenzinga•Oct 29, 2025, 01:03 PM
10x Genomics And Anthropic Announce A Collaboration Integrate 10x's Analysis Tools Into The Newly-Launched Claude For Life Sciences Offering The Model Context Protocol
📈 PositiveBenzinga•Oct 20, 2025, 04:32 PM
Piper Sandler Initiates Coverage On 10x Genomics with Neutral Rating, Announces Price Target of $15
➖ NeutralBenzinga•Sep 11, 2025, 11:23 AM
10x Genomics And CLISEQ Announce Translational Research Collaboration For Single Cell Applications In Hematology Clinical Diagnostics
📈 PositiveBenzinga•Sep 9, 2025, 01:05 PM
10x Genomics Launches Xenium Protein
📈 PositiveBenzinga•Aug 19, 2025, 01:13 PM
Frequently Asked Questions about TXG
What is TXG's current stock price?
10x Genomics, Inc. (TXG) is currently trading at $16.05 per share. The stock has moved +0.31% today.
What is the analyst price target for TXG?
The average analyst price target for TXG is $21.00, based on 1 analyst.
What sector is 10x Genomics, Inc. in?
10x Genomics, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is TXG's market cap?
10x Genomics, Inc. has a market capitalization of $1.98 billion, making it a small-cap company.
Does TXG pay dividends?
No, 10x Genomics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCERT
Certara, Inc.
$9.07
Mkt Cap: $1.5B
GRDN
Guardian Pharmacy Services, Inc.
$31.54
Mkt Cap: $2.0B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
NUVB
Nuvation Bio Inc.
$9.44
Mkt Cap: $3.2B
OMCL
Omnicell, Inc.
$46.84
Mkt Cap: $2.2B
OMDA
Omada Health
$14.50
Mkt Cap: $0.8B
PGNY
Progyny, Inc.
$26.63
Mkt Cap: $2.3B
SDGR
Schrödinger, Inc.
$17.66
Mkt Cap: $1.3B
SION
Sionna Therapeutics, Inc.
$42.37
Mkt Cap: $1.9B
TDOC
Teladoc Health, Inc.
$7.23
Mkt Cap: $1.3B
Explore stocks similar to TXG for comparison